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Abstract
Worsening donor liver quality resulting in decreased organ utilization may be contributing to the
recent decline in liver transplants nationally. We sought to examine trends in donor liver
utilization and the relationship between donor characteristics and non-use. We used the United
Network for Organ Sharing database to review all deceased adult organ donors in the United
States who had at least one solid organ transplanted into a recipient. Trends in donor
characteristics were examined. Multivariate logistic regression was used to evaluate the
association between donor characteristics and liver non-use between 2004 and 2010. Population
attributable risk proportions were determined for donor factors associated with non-use. 107,259
organ donors were analyzed. The number of unused livers decreased steadily from 1,958 (66% of
donors) in 1988 to 841 (15%) in 2004, but then gradually increased to 1,345 (21%) in 2010. Donor
age, body mass index (BMI), and the prevalence of diabetes and donation after cardiac death
(DCD) all increased over time, and all four were independently associated with liver non-use.
DCD had the highest adjusted odds ratio (OR) for non-use, and the odds increased nearly four-fold
between 2004 (OR 5.53; 95% CI, 4.57–6.70) and 2010 (OR 21.31; 95% CI, 18.30–24.81). The
proportion of non-use attributable to DCD increased from 9% in 2004 to 28% in 2010. The
proportion of donor livers not used has increased since 2004. Older donor age, greater BMI,
diabetes, and DCD are all independently associated with non-use and are on the rise nationally.
Current trends may lead to significant declines in liver transplant availability.
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INTRODUCTION
Liver transplantation is the treatment of choice for patients with end-stage liver disease, but
utilization is limited by inadequate organ availability (1). Efforts to expand the donor pool
have included living donation, split liver transplantation, and the use of extended criteria
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donors, which include older donors, donors with fatty livers, and donation after cardiac
death (DCD) donors (1).
Although the intention of extended criteria donation is to increase transplantation, post-
transplant outcomes can be inferior when such organs are used (2–8). DCD grafts, procured
after donor circulation ceases, are subject to a period of poor perfusion during the asystolic
phase, leading to ischemic bile duct damage (9). Consequently, they carry increased risk of
recipient morbidity and mortality compared to standard donation after brain death (DBD)
grafts, which are procured while circulation is supported (4, 7). DCD transplants are also
associated with longer hospital length of stay and increased cost (10), and may not be cost-
effective compared to a strategy of remaining on the transplant waiting list until a DBD liver
is available (11). Advanced donor age and graft steatosis (fatty liver) are also associated
with graft failure (2, 3, 5). For these reasons, transplant centers are more likely to reject liver
offers from DCD donors, older donors, and donors with liver steatosis (12, 13).
Following years of liver transplantation growth in the United States, the annual number of
deceased donor transplants has fallen since 2006 (14). The reasons for this decline are
unclear but are not entirely due to stagnant donation rates since the decline in liver
transplants has exceeded the decline in organ donors (14). One potential reason for the
decline is that of increasing donor liver non-use due to unacceptable organ quality (15). As
the population ages (16) and becomes increasingly obese (17), increasing extended criteria
donation could contribute to increasing non-use. It also remains unclear whether the attempt
to increase the number of available livers by increasing DCD is being undermined by
increased non-use of such livers.
Organ donors who have at least one organ used for transplantation are of particular interest
because they lack an absolute contraindication to organ donation, such as an infectious
condition that could be transmitted to the recipient. Liver non-use within this group of
successful organ donors is therefore likely due to particular issues with liver quality. We
sought to evaluate the association between various donor characteristics and liver non-use
among this subgroup of organ donors in the United States and to examine temporal trends in
characteristics that may explain the decline in liver transplants.
METHODS
Data Source and Study Population
We utilized the United Network for Organ Sharing (UNOS) standard transplant analysis and
research files, which contain information on all deceased donors in the United States since
October 1, 1987. We limited the sample to donors ≥ 18 years old who had at least one organ
(liver, heart, intestine, kidney, lung, or pancreas) transplanted into a patient. Split liver
donations were excluded given the likely differences in liver quality required for split livers
as compared to whole livers. Donors with a body mass index (BMI) < 14 or > 50 kg/m2
were also excluded, since these were likely the result of data entry errors.
Dependent Variable
The primary outcome was donor liver non-use, defined as a liver that was not procured or a
liver that was procured but not transplanted.
Independent Variables
The key variables of interest were age, BMI, diabetes, hypertension, and DCD. BMI,
diabetes and hypertension were chosen because of their associations with non-alcoholic fatty
liver disease (NAFLD) (18). Liver histology was available for only 30% of donors and
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therefore was not included in the main analyses. It was included as a secondary analysis as a
dichotomized variable (macrosteatosis < 30% versus ≥ 30%) (19). Because the relationship
between age and organ non-use was not linear, we specified age categorically (< 30, 30–39,
40–49, 50–59, and ≥ 60 years); similarly, we specified BMI categorically (< 18.5, 18.5–24+,
25–29+, 30–39+, and ≥ 40 kg/m2).
We examined additional donor factors that could be associated with the decision to use a
liver (5, 13). We considered year of organ recovery (continuous), sex, race as determined by
the organ procurement organization (white, black, or other), cause of death (trauma,
cerebrovascular accident [CVA], or other), lifetime smoking (> 20 pack-years), alcohol use
(≥ 2 drinks per day), history of illicit drug use, presence of infection, inotrope use at cross-
clamp, history of malignancy, alanine aminotransferase (ALT), bilirubin, hepatitis C
antibody, hepatitis B core antibody, blood type, and UNOS region. Within the subgroup of
DCD donors, prolonged warm ischemia time (WIT) (> 20 minutes) was also evaluated (20).
ALT and bilirubin were not normally distributed, and were categorized as ≤ 40, 41–200,
201–400, > 400 U/L, and ≤ 1.2, 1.3–2.5, 2.6–5, > 5 mg/dL, respectively. Aspartate
aminotransferase was not included due to collinearity with ALT. Donor height, a component
of the donor risk index (5), was not included because it is also a component of BMI.
Time Periods and Missing Data
Trends in donor characteristics and liver utilization were examined from 1988 to 2010. All
other descriptive and multivariate analyses were restricted to recoveries performed between
June 30, 2004, and December 31, 2010. We selected this time period for our analyses due to
completeness of UNOS data and our interest in recent causes of liver non-use. In particular,
alcohol intake was not systematically recorded prior to this time. BMI, diabetes,
hypertension, DCD, and laboratory values were available since 1995 with varying degrees
of completeness. However, from 2004 onward, each individual variable of interest was
missing in < 3% of donors. All variables were present in 92% of donors.
Statistical Analysis
Categorical variables were reported as proportions and counts. Continuous variables were
reported as means and standard deviations (SD) when normally distributed and as medians
and ranges otherwise. Bivariate comparisons between categorical variables were performed
with Pearson’s χ2 test. Comparisons between continuous variables were performed with
Student’s t-test or the Wilcoxon rank-sum test, where appropriate. Multivariate logistic
regression was used to examine associations between donor characteristics and liver non-
use, controlling for all independent variables. Since transplant center practices may change
over time, we assessed potential interactive effects between year and all other variables
using the likelihood ratio test. For instance, we hypothesized that centers may be more likely
to use livers from older donors over time since the population is aging and emphasis has
been placed on extended criteria donors nationally (21). Interaction terms for age and DCD
with year were statistically significant, improved overall model fit, and were included in the
final model. Other interaction terms were omitted from final model estimations.
Subgroup analyses were performed using additional logistic regression models. For the 30%
of donors who had histology results available, the association between macrosteatosis and
non-use was evaluated. To explore trends in the utilization impact of DCD for individual
UNOS regions, a model was constructed including interaction terms for UNOS regions with
DCD. To determine if there were differences in odds ratios (ORs) for donor characteristics
between the DBD and DCD subgroups, interaction terms between DCD and all other factors
were included in another model. Within the subgroup of DCD donors, the association
Orman et al. Page 3










between prolonged WIT and non-use was also determined using logistic regression,
adjusting for all other independent variables.
To determine the relative impact of each factor on the overall non-use of livers, population
attributable risk proportions (PARP)s were calculated (22). Despite being labeled
“proportions”, PARPs of various donor characteristics do not sum to 100% because the
characteristics overlap and the PARPs are not independent. Separate PARPs were calculated
by year to illustrate temporal trends. Variance-weighted least squares linear regression was
used to test trends of PARPs.
All p-values were based on 2-sided tests, and were considered statistically significant when
p < 0.05. Analyses were performed using Stata version 12 (StataCorp LP, College Station,
TX). The University of North Carolina Institutional Review Board approved this study.
RESULTS
Study Population Characteristics
107,259 individuals meeting inclusion and exclusion criteria donated at least one organ
between January 1, 1988, and December 31, 2010. 41,503 (38.7%) donated after June 30,
2004. After this date, the liver was used for transplant in 33,895 (81.7%), and 7,608 (18.3%)
were unused. The liver was used in 89.6% of successful heart donors, in 99.7% of intestine
donors, in 78.4% of kidney donors, in 90.2% of lung donors, and in 96.9% of pancreas
donors. When more than one organ was used, 95% of livers were used. When only one
organ was used, 51.2% of these were livers; 46.5% were one or both kidneys; and hearts,
intestines, lungs, and pancreas each comprised < 2%. The mean donor age was 43.7 years,
40.9% were female, and 68.4% were white (Table 1). The mean BMI was 27.4 kg/m2,
10.9% had diabetes, and 36.3% were hypertensive. 9.0% were DCD donors. 18.4% had an
alcohol use history, 34.0% had a history of drug use, 3.8% were hepatitis C antibody
positive, and 42.2% had ALT > 40 U/L. 13.7% of those with available histology had ≥ 30%
macrosteatosis.
Temporal Trends in Donor Characteristics and Liver Utilization
Mean donor age increased from 34.6 to 43.3 between 1988 and 2010. During this time, the
percentage aged 18–39 decreased from 65.6% to 40.3% while the percentage ≥ 50 increased
from 16.0% to 38.0% (Figure 1A). 84.9% were white in 1988, whereas 67.1% were white in
2010. The prevalence of obesity (BMI ≥ 30 kg/m2) increased from 15.0% in 1995 to 30.3%
in 2010 (Figure 1B). The prevalence of diabetes and hypertension both increased from 3.2%
and 22.6% in 1995, to 12.0% and 37.2% in 2010, respectively (Figure 1C, D). 65.1% had
ALT < 40 U/L in 1995, whereas 56.2% had ALT < 40 U/L in 2010. Bilirubin, however, did
not change substantially. DCD increased from 44 (1.1% of donors) in 1995 to 730 (11.2%)
in 2010 (Figure 2). Since 2006, the rise in DCD has been accompanied by a proportionate
decline in DBD donation. The percentage of livers not used fell between 1988 and 2004
from 66.2% to 14.8%, after which it increased to 20.7% (Figure 2). This utilization pattern
was seen across UNOS regions, even in Region 9, which traditionally has been the most
aggressive user of expanded criteria livers (Figure 3) (23). Between 1995 and 2010, the
proportion of donors who only had one organ used increased slightly from 25.8% to 30.6%.
Each year, the median number of organs used was 2. Within the group who only had one
organ used, 25.6% were livers in 1995. This figure increased to 59.1% in 2004, and then fell
to 45.5% in 2010. Conversely, 67.2% were kidneys in 1995. Kidneys fell to 38.2% in 2004
and then increased to 52.2% in 2010.
Orman et al. Page 4










Characteristics of DCD Donors
DCD donors were, on average, younger than DBD donors (mean age 41.3 vs. 43.9 years, p <
0.001) (Table 1). Mean BMIs of DCD and DBD donors were 27.7 and 27.3 kg/m2,
respectively (p < 0.001). Diabetes and hypertension were more common in DBD donors.
DCD donors were more likely to be white, to have a history of drug or alcohol use, and to
have ALT > 40 U/L. DBD donors were more likely to be female, to have a CVA cause of
death, to have elevated bilirubin, and to have viral hepatitis exposure. DBD donors were also
more likely to receive inotropic support. For DCD, the median WIT was 15 minutes
(interquartile range 10–24). The WIT was prolonged (> 20 minutes) in 34.3%. The
prevalence of prolonged WIT fell from 41.1% in 2002 to 26.7% in 2005, and then returned
to 41.1% in 2010.
Liver Non-Use According to Donor Characteristics
In bivariate analyses, non-use was associated with increasing donor age up to 60, above
which the liver was more likely to be used. Compared to normal weight donors, those with
higher and lower BMI were less likely to be used. Diabetes and hypertension were both
associated with non-use. 58.2% of DCD livers were not used as compared to 14.4% of DBD
livers. Livers from black donors were more likely to be used. Non-use was also associated
with smoking, alcohol use, increasing ALT and bilirubin, and exposure to viral hepatitis. Of
those with histology available, 9.4% of livers were not used when macrosteatosis was <
30%, and 52.9% were not used when ≥ 30%. Within the DCD subgroup, 67.9% of livers
were not used when the WIT was > 20 minutes, and 52.9% were not used when it was ≤ 20
minutes.
In multivariate analysis, liver non-use was associated with increasing donor age up to 60
(Table 2). As in the bivariate analysis, livers from donors older than 60 were more likely to
be used than those from donors aged 50–59. The strength of the association between age and
liver non-use increased over time (p for interaction = 0.002). DCD was strongly associated
with liver non-use, and this relationship became more pronounced over time. The OR for
DCD increased from 5.53 (95% CI 4.57–6.70) in 2004 to 21.31 (95% CI 18.30–24.81) in
2010 (p for interaction < 0.001). High and low BMI and diabetes were associated with non-
use, but hypertension was not (Table 3). Black race and illicit drug use were independently
associated with organ use, whereas female sex, “other” race, CVA cause of death, alcohol
use, increasing ALT and bilirubin, and hepatitis C antibody were associated with non-use.
Macrosteatosis ≥ 30% was strongly associated with non-use among those with histology
available (adjusted OR 11.16; 95% CI 9.75–12.77). The ORs for most factors were similar
in DBD and DCD donors. The strength of the associations between non-use and ages 30–50,
alcohol use, non-trauma causes of death, and elevated ALT were greater for DBD than for
DCD donors (Table 4). In contrast, age > 50 was more strongly associated with non-use in
DCD donors. Among DCD donors, prolonged WIT was associated with non-use (adjusted
OR 2.06; 95% CI 1.71–2.47).
Population Attributable Risks for Liver Non-Use
DCD accounted for 8.7% of liver non-use in 2004; this proportion increased to 28.4% in
2010 (Figure 4). PARPs for DCD increased over time in all regions except Region 6 where
it peaked at 18.8% in 2006 and fell to 15.3% in 2010. The proportion of non-use due to age
≥ 50 increased from 16.7% in 2004 to 22.9% in 2010. No other factor increased its impact
on organ non-use by more than 5% during this time. In 2010, BMI ≥ 25 kg/m2 explained
17.5% of non-use, but diabetes explained only 1.0% (Table 5). White race (compared to
black race) was responsible for 16.8% of non-use. Alcohol use accounted for 10.9% of
organ non-use, ALT > 40 U/L accounted for 19.9%, bilirubin > 1.2 mg/dL accounted for
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9.9%, and hepatitis C antibody accounted for 2.3%. The PARP for prolonged WIT within
the DCD subgroup remained unchanged during the study period (8.1%, p for trend = 0.36).
DISCUSSION
The recent decline in the number of liver transplants performed in the United States is
multifactorial. One potential reason for this decline is a decrement in donor organ quality
leading to a decrease in utilization. In this study of all donors in the US who had at least one
organ used for transplant, we found that the proportion of livers not used reversed its
downward trend in 2004, thereafter rising through 2010 (Figure 2). In 2004, 841 of 5,680
(14.8%) donated livers were not used. Of the 6,506 livers donated in 2010, 1,345 (20.7%)
were not used. Had the rate of non-use remained stable at 14.8%, 382 more livers from this
group would have been transplanted in 2010.
Older donor age, higher BMI, and diabetes are independently associated with liver non-use.
As in the general population (16, 17), all of these factors have become more common in the
donor population over a long time period (Figure 1). Therefore, these findings suggest that
the quality of donated livers has been declining for many years. Despite this deteriorating
quality, non-use continued to decrease before 2004 possibly as a result of the gradual
expansion of extended criteria donor liver use while maintaining acceptable post-transplant
outcomes (24). However, the tolerance for worse outcomes with extended criteria donor
livers has probably reached a limit, thus leading to declining utilization since 2004.
DCD is also independently associated with liver non-use. In contrast to age, BMI, and
diabetes, the increase in the prevalence of DCD and the nearly four-fold increase in the odds
of having DCD livers not used are particularly remarkable. This increasing reluctance to use
DCD livers is undoubtedly the result of growing recognition that post-transplant outcomes
are worse, and may be compounded by increased Medicare scrutiny of transplant programs’
outcomes (25). Such reluctance is further justified by recent data demonstrating that patients
with low Model for End-Stage Liver Disease scores and those with hepatocellular carcinoma
exception points may be better served by declining DCD organs and waiting for a DBD liver
(11). Although prolonged WIT is associated with non-use amongst DCD livers, this
association did not translate into a rising PARP for prolonged WIT alone, perhaps due to
fluctuating rates of prolonged WIT over time. Despite the relatively recent growth of DCD,
it appears to be overtaking the other factors as a common reason for liver non-use. By 2010,
DCD accounted for more than one quarter of unused livers. This increasing impact of DCD
and decreasing utilization was seen across UNOS regions and is not the result of an outlier
region influencing national trends. Even Region 9, which historically has been significantly
more likely to use marginal quality livers (23), showed a similar increase in non-utilization
since 2004 compared to other regions (Figure 3).
Others have raised concerns about increasing reliance on DCD. In the Netherlands, DCD
increased while DBD decreased, resulting in no net gain of grafts for kidney transplantation
(26). A 2005 conference took note of this trend, and compared it to the United States
experience, where increasing DCD was accompanied by increases in DBD. They concluded,
“The evolving DCD practice is expected to result in an absolute increase of organ donors,
i.e. in addition to DBD” (27). Our results show that DBD has declined while DCD has
increased (Figure 2), refuting this prediction.
A worrisome possible explanation for this pattern is that the withdrawal of cardiovascular
support preceding DCD is occurring in donors who would have eventually progressed to
brain death, thus “converting” potential DBD donors to less desirable DCD. The reasons for
possible conversions are unclear. There may be a growing preference for DCD among donor
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families and intensive care providers as they have become more educated on the DCD
option. The Organ Donation Breakthrough Collaborative may have reinforced this
preference by emphasizing DCD as a method to expand the donor pool (28), particularly
since DCD kidney transplant outcomes are comparable to DBD (29). Indeed, we found that
among donors who only had one organ used, livers have been declining while kidneys have
been increasing since 2004. Alternatively, aggressive neurological management of donors
may prevent the development of brain death (30). Such intensive neurological management
has become more common and is associated with DCD (31).
DCD has become more popular in recent years as a means to capture organs that would not
otherwise be available. The challenge is discerning between these situations of net organ
gain versus DBD to DCD conversions where the net gain of donated livers is nil.
Unfortunately, our findings suggest that conversions could explain the rise in DCD since
DBD has declined. Such conversions would be neutral in terms of number of transplanted
livers were it not for the increasing reluctance to use DCD livers. The transplant community
must consider ways to capture data on any potential conversion problem. If such a problem
exists, its harm to liver utilization could be vast.
While the OR for not using a liver because of older age was less than that of DCD, the
overall impact of age remains greater because advancing age is more common than DCD,
and even a modest increase in age (≥ 30 years) is associated with non-use. The lower OR for
those ≥ 60 compared to 50–59 year olds has been reported previously (13), and likely
reflects selection bias for only the healthiest older individuals being considered for donation.
Like DCD, the impact of age on liver non-use is increasing, but less rapidly. Obesity is also
becoming more prevalent among donors, but the overall impact of obesity has not increased,
likely because of the relatively modest ORs for overweight and obese donors. Nevertheless,
the population-level impact of obesity on liver non-use may increase in the future as its
prevalence increases.
Elevated donor ALT is becoming more common, is associated with liver non-use, and has a
substantial impact on overall utilization. The greatest increase in ALT prevalence was
among those with a mild-to-moderate elevation (41–200 U/L). Whether this finding
represents another manifestation of NAFLD is unknown, but if true, would also bode poorly
for future organ quality. In contrast, black race was strongly associated with organ use as
compared with white race. The reasons for this difference are unclear, but could potentially
relate to the lower prevalence of NAFLD in blacks as compared to other races (32). This
finding takes on particular importance because of lower rates of organ donation in the black
population (15).
DBD and DCD donors represent two distinct populations, and one might expect that the
relationships between donor factors and non-use would differ between these groups.
However, ORs for non-use were actually similar for most donor factors. When different,
most associations were attenuated in the DCD group, likely representing selection bias for
DCD donors deemed acceptable for the use of at least one organ.
Additional external factors could impact liver utilization. DonorNet is the electronic UNOS
system that has been used to facilitate organ placement since April 30, 2007. Through
DonorNet, electronic organ offers can be made simultaneously to multiple recipient centers
with detailed donor information available electronically to increase efficiency and improve
utilization. Prior to the use of DonorNet, organ offers were made manually, which limited
communication and decision making in the donor-recipient matching process. After
DonorNet was implemented, there was an increase in the percentage of recovered livers that
were discarded, particularly among those with the highest donor risk indices (33). However,
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our findings show that utilization was already decreasing before DonorNet was
implemented, so its effect on utilization remains unclear.
The main limitation of this study is the lack of detail on reasons for the rise in liver non-use.
The reasons for organ non-use are recorded broadly in the database as “poor organ function”
or “biopsy findings.” The dataset also lacked sufficient biopsy data to directly link donor
steatosis to organ non-use, as only 30% of donors had biopsy data. However, obesity and
diabetes are strongly associated with NAFLD (18) and have previously been used as
surrogates for steatosis (13). Although we did find an association between steatosis and non-
use within the subgroup that had available histology, this represents a biased sample, as
donors who receive a liver biopsy are highly selected. Therefore, the estimate for this
relationship cannot be generalized to the entire donor population, and the overall PARP was
not calculated. Finally, this study does not address the stagnation in rates of overall donation
that is impacting the national volume of transplants (15). However, utilization of available
organs becomes even more critical if we cannot rely on expanding donation.
Despite these shortcomings, the UNOS database is well suited to address our study goal,
which was to report national trends in organ utilization. The database has complete coverage
of all donors and organ dispositions nationwide. Misclassification of our primary outcome
and DCD is probably rare and unlikely to affect our results. Misclassification of other
variables such as diabetes may be more likely, but is probably non-differential and would
therefore bias the results toward the null.
Among organ donors in the United States who had at least one organ used for transplant, we
found that the non-use of livers fell until 2004 and has since increased. Concurrently, the
prevalences of advanced donor age, elevated BMI, diabetes, and DCD have all increased.
These factors are associated with liver non-use, and the impact of DCD on non-use has
grown rapidly. A better understanding of the reasons for the increasing proportion of DCD
in particular is critical to understanding this declining utilization. These trends, along with
stagnant donation rates, suggest significant declines in liver transplant availability in the
coming years.
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Temporal trends in (A) age, (B) BMI, (C) diabetes, and (D) hypertension expressed as
percentages among donors of at least one solid organ.
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Trends in donation after cardiac death and liver non-use, 1995–2010. The bars denote the
absolute numbers of donors who had at least one solid organ transplanted, according to
donation after cardiac death (DCD) versus donation after brain death (DBD) (left axis). The
line denotes the percentage of liver grafts unused among those donors who donated at least
one organ (right axis).
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Temporal trends in liver non-use across UNOS regions among donors of at least one solid
organ. Region 9 is depicted with a bold black line, compared to the other 10 regions in gray.
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Percentage of overall liver graft non-use among donors of at least one solid organ due to
donation after cardiac death, by year. These values are calculated as the population
attributable risk proportions, based on the adjusted odds ratios for non-use and annual
prevalence of DCD.
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Table 2
Trends in Adjusteda Odds Ratios for Liver Non-Use by Donor Age and Donation After Cardiac Death
Yearb 2004 2010
Age, years
 < 30 1 [Ref] 1 [Ref]
 30–39 1.43 (1.14–1.79) 1.68 (1.38–2.04)
 40–49 1.87 (1.54–2.29) 2.69 (2.27–3.20)
 50–59 2.14 (1.75–2.62) 3.44 (2.89–4.10)
 ≥ 60 1.67 (1.33–2.10) 3.11 (2.55–3.80)
Donation after cardiac death 5.53 (4.57–6.70) 21.31 (18.30–24.81)
a
Based on the multivariate logistic regression model adjusted for all of the variables in Table 3 as well as UNOS region and ABO blood type.
b
Interaction terms for age by year and donation after cardiac death by year were significant; odds ratios for the years 2004 and 2010 are presented.
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Table 3
Non-Use of Liver Grafts According to Donor Characteristics, Multivariate Analysis
Characteristic (N = 38,319) Adjusted ORa (95% CI)
Female 1.14 (1.07–1.21)
Race
 White 1 [Ref]
 Black 0.62 (0.56–0.69)
 Other 1.49 (1.37–1.62)
Body mass index, kg/m2
 < 18.5 1.32 (1.09–1.60)
 18.5–24+ 1 [Ref]
 25–29+ 1.17 (1.08–1.26)
 30–39+ 1.97 (1.82–2.14)




 Trauma 1 [Ref]
 CVA 1.16 (1.06–1.25)
 Other 0.89 (0.81–0.97)
Smoking 0.98 (0.92–1.05)
Alcohol use 2.57 (2.39–2.77)
Illicit drug use 0.80 (0.74–0.86)
Infection 1.03 (0.96–1.10)
Inotrope support 1.09 (1.02–1.16)
Cancer history 0.91 (0.77–1.07)
ALT, U/L
 ≤ 40 1 [Ref]
 41–200 1.70 (1.59–1.82)
 201–400 3.16 (2.72–3.66)
 > 400 10.66 (9.28–12.24)
Bilirubin, mg/dL
 ≤ 1.2 1 [Ref]
 1.3–2.5 1.53 (1.42–1.65)
 2.6–5 2.98 (2.63–3.39)
 > 5 9.91 (7.92–12.41)
Hepatitis C antibody 2.78 (2.42–3.18)
Hepatitis B core antibody 1.13 (0.99–1.28)
Abbreviations: OR, odds ratio; CI, confidence interval; CVA, cerebrovascular accident; ALT, alanine aminotransferase.
a
Based on the multivariate logistic regression model adjusted for all of the other variables in the table as well as age, donation after cardiac death,
UNOS region and ABO blood type.
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Table 4
Adjusteda Odds Ratios for Liver Non-Use for Donor Characteristics that Differb by DCD Status
Characteristic DBD DCD
Age in 2010,c years
 < 30 1 [Ref] 1 [Ref]
 30–39 1.88 (1.53–2.31) 1.21 (0.92–1.59)
 40–49 2.80 (2.32–3.37) 2.41 (1.88–3.09)
 50–59 3.36 (2.78–4.05) 4.20 (3.23–5.45)
 ≥ 60 3.01 (2.44–3.73) 9.83 (6.38–15.15)
Alcohol use 2.68 (2.47–2.90) 1.85 (1.51–2.26)
Cause of death
 Trauma 1 [Ref] 1 [Ref]
 CVA 1.21 (1.11–1.32) 0.88 (0.71–1.09)
 Other 0.85 (0.77–0.95) 0.95 (0.79–1.14)
ALT, U/L
 ≤ 40 1 [Ref] 1 [Ref]
 41–200 1.83 (1.70–1.97) 1.13 (0.97–1.33)
 201–400 3.30 (2.81–3.87) 2.48 (1.64–3.74)
 > 400 11.51 (9.95–13.31) 5.94 (3.75–9.41)
Abbreviations: DCD, donation after cardiac death; DBD, donation after brain death; CVA, cerebrovascular accident; ALT, alanine
aminotransferase
a
Based on the multivariate logistic regression model adjusted for all of the variables in Tables 2 & 3 as well as UNOS region and ABO blood type.
b
Interaction terms for the listed variables by donation after cardiac death were significant; odds ratios for the DBD and DCD subgroups are
presented.
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Table 5
Percentagea of overall liver graft non-use due to donor characteristics in 2010
Characteristic % of non-useb (95% CI)
Age
 < 30 [Ref]
 30–39 3.7 (2.3–5.1)
 40–49 11.6 (9.7–13.6)
 50–59 15.3 (13.2–17.2)
 ≥ 60 7.6 (6.2–9.0)
Female 3.0 (1.5–4.5)
Race
 White 16.8 (13.3–20.3)
 Black [Ref]
 Other 7.8 (6.7–8.8)
Body mass index
 < 18.5 0.3 (0.1–0.6)
 18.5–24+ [Ref]
 25–29+ 2.7 (1.3–4.1)
 30–39+ 10.7 (9.4–11.9)





 CVA 3.5 (1.5–5.4)
Alcohol use 10.9 (10.0–11.9)
Inotrope support 2.4 (0.5–4.2)
ALT, U/L
 ≤ 40 [Ref]
 41–200 11.0 (9.6–12.4)
 201–400 2.9 (2.4–3.3)
 > 400 6.0 (5.5–6.4)
Bilirubin, mg/dL
 ≤ 1.2 [Ref]
 1.3–2.5 4.3 (3.5–5.1)
 2.6–5 2.9 (2.5–3.3)
 > 5 2.6 (2.3–2.9)
Hepatitis C antibody 2.3 (2.0–2.7)
Abbreviations: CI, confidence interval; DCD, donation after cardiac death; CVA, cerebrovascular accident; ALT, alanine aminotransferase.
a
Calculated as the population attributable risk proportion, based on the multivariate logistic regression model.
b
Percentages do not sum to 100% because population attributable risk proportions are not independent.
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